This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Testosterone enantate parenteral


Injections of testosterone enantate.

Drugs List

  • testosterone enantate 250mg/1ml oily injection
  • Therapeutic Indications


    Androgen deficiency

    Unlicensed Uses

    Carcinoma of breast
    Sexual maturation in males: induction and maintenance of


    Serum levels below normal range would indicate the need for a shorter injection interval. In case of high serum levels an extension of the injection interval may be considered.


    Androgen deficiency
    Initial treatment of deficiency symptoms: 250mg every two to three weeks.
    Maintenance treatment: 250mg every three to six weeks, according to individual requirement.

    Carcinoma of breast (unlicensed)
    250mg every two to three weeks.


    Induction and maintenance of sexual maturation in males (unlicensed)
    To be given under specialist supervision.
    Children aged 12 to 18 years: 25 to 50mg/metre squared every month. Increase dose every six to twelve months, titrated to response.


    Administer by slow intramuscular injection only.


    Children under 12 years
    Androgen-dependent neoplasm
    Breast cancer in males
    Hepatic neoplasm
    History of hepatic neoplasm
    Nephrotic syndrome

    Precautions and Warnings

    Children aged 12 to 18 years
    Predisposition to fluid retention
    Predisposition to hypercalcaemia
    Prepubertal males
    Cardiac impairment
    Diabetes mellitus
    Epileptic disorder
    Hepatic impairment
    Ischaemic heart disease
    Renal impairment
    Skeletal metastasis
    Sleep apnoea

    Adjustment of hypoglycaemic therapy may be necessary in diabetes mellitus
    Monitor testosterone levels at baseline and periodically during treatment
    If upper abdominal complaints/liver enlargement consider liver tumour
    Monitor hepatic function, haematocrit and haemoglobin in long term therapy
    Monitor serum lipids
    Potential for drug abuse
    Regular examination of prostate advised to exclude prostatic cancer
    If frequent/persistent erections occur reduce dose/discontinue
    Increased risk of premature sexual development+epiphyseal closure in boys
    Discontinue if oedema progresses or signs of cardiac failure occur
    Not licensed for all indications in all age groups
    May affect spermatogenesis

    Measure serum testosterone levels before the start of treatment and at various points during treatment once an injection interval has finished. Serum levels below the normal range would require shorter injection intervals whereas high serum levels may require an extension of injection intervals.

    Pregnancy and Lactation


    Testosterone enantate is contraindicated during pregnancy.

    The manufacturer does not recommend using testosterone enantate during pregnancy.


    Testosterone enantate is contraindicated during breastfeeding.

    The manufacturer does not recommend using testosterone enantate during breastfeeding.

    Side Effects

    Abdominal disorders
    Abnormal liver function tests
    Changes in libido
    Cholestatic jaundice
    Circulatory disturbances
    Fluid retention
    Gastrointestinal bleeding
    Hepatic tumours
    Hypersensitivity reactions
    Increase in haematocrit
    Increase in haemoglobin
    Increase in prostate specific antigen (PSA)
    Increased bone growth
    Injection site reactions
    Interference with spermatogenesis
    Intra-abdominal haemorrhage
    Male pattern baldness
    Precocious sexual development (pre-pubertal males)
    Premature closure of epiphyses (in pre-pubertal males)
    Prostate abnormalities
    Prostate cancer
    Rarely coughing, dyspnoea and circulatory disorders
    Virilism in females


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2019

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Testosterone Enantate Ampoules. Alliance Pharmaceuticals. Revised October 2016.

    NICE Evidence Services Available at: Last accessed: 08 August 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.